Bedrijfsoverzicht
Celldex Therapeutics, Inc. is a biopharmaceutical entity dedicated to the development of therapeutic antibodies intended for patients suffering from severe inflammatory, allergic, autoimmune, and other related diseases. The corporation operates specifically within the Healthcare sector and functions in the Biotechnology industry, which typically involves high-risk research and development activities aimed at bringing novel medical treatments to market. The company currently maintains a market capitalization of $2.53 billion and employs a workforce of 198 individuals to support its operational and research objectives. Despite a reported annual revenue of $1.54 million, the substantial market cap indicates a significant valuation premium relative to its current financial performance, suggesting that investors are pricing in future potential rather than current cash generation.
Financiële gezondheid
The company reported trailing twelve-month revenue of $1.54 million alongside a net income of $-258,756,992 and an EBITDA of $-283,987,008. The substantial discrepancy between the minimal revenue and the massive negative net income reveals an aggressive cost structure where operating expenses, likely driven by research and development, far exceed income generation. Free cash flow stands at $-125,544,376, which indicates that the company is consuming cash reserves to fund its operations and development pipeline rather than generating liquidity from its current business model. The balance sheet shows a cash position of $518.57 million against a debt level of $2.34 million, creating a highly conservative leverage profile with a debt-to-equity ratio of 0.44. This liquidity cushion allows the firm to sustain its negative cash flow for an extended period without immediate solvency concerns. The current ratio of 10.48 further confirms exceptional short-term liquidity, suggesting the company holds significantly more current assets than current liabilities. However, return metrics highlight the financial strain, with a return on equity of -40.6% and a return on assets of -26.1%, indicating that management is currently destroying value on the capital base due to heavy losses. Additionally, the gross margin is 0.0%, the operating margin is -72027.3%, and the profit margin is 0.0%, all reflecting the pre-revenue or early-stage nature of the business where costs are incurred without corresponding gross sales volume.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A, while the forward P/E is -6.77, a divergence that implies the market expects earnings to improve significantly in the future to reach a positive multiple. The price-to-book ratio is 4.07, indicating that the market values the company at over four times its net asset value, which often occurs in biotechnology firms where intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 1637.31 and an EV/EBITDA of -5.74 suggest that traditional earnings-based valuations are not applicable, forcing reliance on revenue multiples or asset-based approaches that reflect the speculative nature of the stock. The 52-week high is $34.52 and the 52-week low is $16.74, meaning the current trading price sits below the annual peak and reflects the volatility typical of small-cap biotech stocks. The beta of 1.20 indicates that the stock's price volatility is 20% higher than the broader market, exposing shareholders to amplified swings in share price relative to general market movements.
Growth & Income
Revenue growth year-over-year is -89.7%, while earnings growth is listed as N/A, meaning that financial performance has deteriorated significantly in terms of top-line sales. Since earnings are not growing faster than revenue (as revenue is contracting), the company is currently facing challenges in stabilizing its income stream. As a non-dividend payer, the company does not distribute a dividend yield, which is N/A, nor does it have a payout ratio, maintaining a payout ratio of 0.0%. This approach necessitates that the company reinvest all available earnings, or lack thereof, into growth initiatives rather than returning capital to shareholders. The overall growth and income profile is characterized by negative revenue expansion and a complete reliance on capital markets or cash reserves to finance operations rather than organic profitability or dividend income.